1. Pharmacokinetics. When is steady state achieved? Steady-state was reached after 4 to 5 days of once-daily dosing with Sulisent 100 mg to 300mg.
|
|
- Rosaline Booth
- 5 years ago
- Views:
Transcription
1
2
3
4 1. Pharmacokinetics How is Sulisent metabolized? Sulisent has a novel mechanism of action that targets the kidneys and allows for excess glucose excretion resulting in urinary calorie loss. Sulisent is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), which mediates the majority of the reabsorption of glucose in the kidneys. Sulisent is well absorbed (65%), highly albumin bound (99%), and is eliminated mostly in the urine and feces. UGT (UDP-glucuronosyl transferase) enzymes assist in metabolism. O-glucuronidation is the major metabolic elimination pathway for Sulisent, which is mainly glucuronidated by UGT1A9 and UGT2B4 to two inactive O-glucuronide metabolites. CYP3A4-mediated (oxidative) metabolism of Sulisent is minimal (approximately 7%) in humans When is steady state achieved? Steady-state was reached after 4 to 5 days of once-daily dosing with Sulisent 100 mg to 300mg. Ref: Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs May;74(7): Pharmacodynamics What is the mechanism of action of Sulisent? The rate of renal glucose reabsorption is elevated in people with type 2 diabetes due to upregulation of both expression and function of sodium-glucose cotransporters 2 (SGLT-2). Sulisent is a selective inhibitor of SGLT2, thereby decreasing renal glucose reabsorption and lowering the renal threshold for glucose (RTG), increasing urinary glucose excretion and, in turn, lowering blood glucose levels. Ref: Chao EC. SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clin Diabetes Jan;32(1):4-11. Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs May;74(7): What is renal threshold for glucose? Sodium-glucose cotransporters (SGLTs), namely SGLT-1 and SGLT-2, facilitate reabsorption of glucose back into the plasma. The renal glucose threshold (RTG) is the plasma glucose concentration above which the glucose reabsorption capacity of the kidney is exceeded as the SGLT becomes saturated and urinary glucose excretion (UGE) occurs. Ref: Chao EC. SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clin Diabetes Jan;32(1):4-11. Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs May;74(7): How much does Sulisent lower the renal threshold for glucose (RTG)? From a starting value of approximately 240 mg/dl, Sulisent reduced RTG to approximately mg/dl over 24 hours in type 2 diabetes patients. These RTG values are above the plasma glucose level at which symptoms of hypoglycaemia typically develop and, on the basis of this, Sulisent is not expected to increase the risk of hypoglycaemia. Ref: Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs May;74(7): Efficacy How does Sulisent affect fasting plasma glucose (FPG) and postprandial plasma glucose (PPG)? In patients with type 2 diabetes, treatment with Sulisent produced clinically and statistically significant improvements in A1C, fasting plasma glucose (FPG), and 2-hour postprandial glucose (PPG), compared to placebo. In a 26-week placebo-controlled clinical study, the placebo adjusted reduction in FPG and PPG reported with Sulisent as monotherapy was 36 mg/dl and 48 mg/dl. How does Sulisent affect HbA1c? Sulisent was effective in reducing A1C in a broad range of patients regardless of disease duration and concomitant use of antihyperglycemic agents to treat type 2 diabetes. Statistically significant improvements in glycemic control relative to placebo were observed with Sulisent when given as monotherapy, as initial add-on therapy with metformin or a sulfonylurea, add-on therapy with metformin and a sulfonylurea, metformin and pioglitazone, or add-on therapy with insulin (with or without other antihyperglycemic agents). In a 26-week placebo-controlled clinical study, the placebo adjusted reduction in HbA1c reported with Sulisent as monotherapy was 0.91%. Canagliflozin Tablets 100 mg
5 What type of efficacy was seen with elderly patients? Sulisent demonstrated statistically significant A1c reductions, FPG and body weight in a 26-week placebo-controlled study of 714 patients aged 55 to 80 years who were inadequately controlled on current antihyperglycemic agents. Mean A1c change from baseline: - Sulisent 100mg showed mean A1c change from baseline of (p<0.001) - Sulisent 300mg showed mean A1c change from baseline of (p<0.001) Ref: Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (Minneap). 2013;41(2): Use in Special Population Can Sulisent be prescribed in patients with renal impairment? In patients with an estimated glomerular filtration rate (egfr) 45 to < 60 ml/min/1.73 m2 [CrCl 45 to < 60 ml/min], the dose of Sulisent is limited to 100 mg once daily. Sulisent should not be initiated in patients with an egfr < 45 ml/min/1.73 m2 [CrCl < 45 ml/min]. Sulisent should be discontinued when egfr is persistently < 45 ml/min/1.73 m2 [CrCl < 45 ml/min] (see Warnings and Precautions and Adverse Reactions). Sulisent should not be used in patients with an egfr < 45 ml/min/1.73 m2 [CrCl < 45 ml/min] as it would not be effective in these patient populations. Can Sulisent be prescribed in patients with hepatic impairment? Mild or moderate hepatic impairment (Child-Pugh class A and B) had no clinically significant effect on the pharmacokinetic profile of Sulisent, but the drug is not recommended for use in patients with severe hepatic disease (Child-Pugh class C) because of the lack of clinical experience with Sulisent in these patients. Ref: Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs May;74(7): Cardiovascular Safety What is the cardiovascular safety data on Sulisent? The preliminary CV safety data from phase 2/3 studies including CANVAS trial suggest no increased CV risk. A pre-specified interim meta-analysis of phase II and III clinical trials with canagliflozin in 9,632 patients with type 2 diabetes, including 4,327 patients with increased cardiovascular risk who are participating in CANVAS, showed a hazard ratio of 0.91 (95 % CI ) for canagliflozin 100 and 300 mg/day (combined) versus placebo for the composite primary endpoint (time to event), which included cardiovascular death, non-fatal stroke, nonfatal myocardial infarction and unstable angina requiring hospitalization. In addition, administration of canagliflozin at therapeutic or supratherapeutic dosages was not associated with any meaningful changes in the corrected QT interval in an appropriately designed randomized trial in 60 healthy subjects. Ref: Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs May;74(7): What is the effect of Sulisent on blood pressure? In an analysis of four 26-week, placebo-controlled studies (N=2313), mean reductions in systolic blood pressure relative to placebo were observed with Sulisent 100 mg (-3.9 mmhg), Sulisent 300 mg (-5.3 mmhg), and placebo (-0.1 mmhg) regardless of antihypertensive medication use at baseline. In this same population, there was a smaller effect on diastolic blood pressure with mean changes of -2.1 mmhg with Sulisent 100 mg, -2.5 mmhg with Sulisent 300 mg, and -0.3 mmhg with placebo, regardless of antihypertensive medication use at baseline. There was no discernible change in heart rate. What is the effect of Sulisent on lipid parameters? In an integrated analysis of four placebo-controlled studies of 26 weeks, patients with type 2 diabetes treated with both doses of Sulisent had increased serum levels of total cholesterol, LDL-C (low density lipoprotein cholesterol), and HDL-C (high-density lipoprotein cholesterol) compared to small changes in placebo, while serum levels of triglycerides decreased compared to placebo. At Week 26, the LDL-C/HDL-C ratio minimally changed compared to baseline in all three treatment groups. Canagliflozin Tablets 100 mg
6 6. Drug Interaction What are the key drug interactions? In clinical studies, the effects of other drugs on canagliflozin were assessed. Ciclosporin, hydrochlorothiazide, oral contraceptives (ethinyl estradiol and levonorgestrel), metformin, and probenecid had no clinically relevant effect on the pharmacokinetics of canagliflozin. Co-administration with rifampicin, a nonselective inducer of several UGT enzymes and drug transporters decreased canagliflozin exposure. These decreases in exposure to canagliflozin may decrease efficacy. If a combined inducer of these UGTs and drug transport systems (e.g., rifampicin, phenytoin, barbituates, phenobarbitol, ritonavir, carbamazepine, efavirenz, St John s wort [Hypericum perforatum]) must be co-administered with Sulisent, monitor HbA1c in patients receiving Sulisent 100 mg once daily. In patients with an egfr 45 to < 60 ml/min/1.73 m2 [CrCl 45 to < 60 ml/min], taking Sulisent 100 mg who are receiving concurrent therapy with a UGT enzyme inducer and who require additional glycemic control, other antihyperglycemic therapies should be considered. Patients taking digoxin or other cardiac glycosides (e.g., digitoxin) should be monitored appropriately Sulisent can increase Cmax of digoxin by 36%. Can Sulisent be used with other antihyperglycemic agents? Sulisent has been studied as monotherapy, as add-on therapy with metformin, sulfonylurea, metformin and sulfonylurea, metformin and a thiazolidinedione (pioglitazone), and as add-on therapy with insulin (with or without other antihyperglycemic agents). Hence, it can be combined with most of the available antihyperglycemic agents. Is there any dose adjustments required for sulfonylurea or insulin when used in combination with Sulisent? When Sulisent is used as add-on therapy with insulin or an insulin secretagogue (e.g., sulfonylurea), a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. 7. Adverse Effects What are the common adverse events associated with Sulisent? Genital mycotic infections are a common adverse event associated with canagliflozin and occur more frequently in females than in males. In clinical trials, the incidence of genital mycotic infections was higher with canagliflozin than with placebo, although most infections were mild to moderate in severity and responded to topical and/or oral antifungal therapies, none were serious and few led to discontinuation. The majority of genital mycotic infections were treated with topical antifungal treatments, either prescribed by a healthcare professional or self-treated while continuing therapy with Sulisent. Also, urinary tract infections were more frequently reported for Sulisent 100 mg and 300 mg (5.9% versus 4.3%, respectively) compared to 4.0% with placebo. Most infections were mild to moderate with no increase in the occurrence of serious adverse events. Subjects responded to standard treatments while continuing canagliflozin treatment. The incidence of recurrent infections was not increased with canagliflozin. Ref: Sulisent Prescribing Information. Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs May;74(7): Can Sulisent be used with DPP4 inhibitors or GLP-1 analoges? As per the ADA/EASD 2015 guidelines SGLT2 inhibitors can be used in combination with DPP4 inhibitors and GLP-1 analoges Ref: Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care Jan;38(1): What type of genital infections are seen in males and females? Vulvovaginal candidiasis (including vulvovaginitis and vulvovaginal mycotic infection) was reported in 10.4% and 11.4% of female patients treated with Sulisent 100 mg and Sulisent 300 mg, respectively, compared to 3.2% in placebo-treated female patients. Most reports of vulvovaginal candidiasis occurred during the first four months of treatment with canagliflozin. Candidal balanitis or balanoposthitis was reported in 4.2% and 3.7% of male patients treated with Sulisent 100 mg and Sulisent 300 mg, respectively, compared to 0.6% in placebo-treated male patients. Canagliflozin Tablets 100 mg
7 Among male patients taking Sulisent, 0.9% had more than one infection. Overall, 0.5% of male patients discontinued Sulisent due to candidial balanitis or balanoposthitis. Phimosis was reported in 0.3% of uncircumcised males in a pooled analysis of 8 controlled trials. Which patients are more prone to genital mycotic infection? Male and female patients with a history of genital mycotic infections were more likely to develop an infection. Genital mycotic infections occurred more frequently in males who were uncircumcised than in those who were circumcised. Ref: 1. Sulisent Prescribing Information dated 28 July Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs May;74(7): What precautions should be taken to prevent genital mycotic infections in males? In general, good hygiene is always recommended, and cleaning beneath the foreskin with soap and water is advised in uncircumcised patients. Inform male patients, especially those not circumcised, of the potential for infection, and provide them with information on the signs and symptoms. Advise patients of treatment options and when to seek medical advice. Ref: Penis health: identify and prevent problems. Mayo Clinic Web site. Accessed July 23, 2015 What precautions should be taken to prevent genital mycotic infections in females? Inform female patients of the potential risk for vulvovaginal candidiasis and provide them with information on signs and symptoms. To help prevent vaginal yeast infections, patients can: Avoid scented hygiene products like bubble bath, sprays, pads, and tampons Change tampons and pads often during your period Avoid tight underwear or clothes made of synthetic fibers Wear cotton underwear and pantyhose with a cotton crotch Change out of wet swimsuits and exercise clothes as soon as you can Avoid hot tubs and very hot baths Does Sulisent increases the risk of hypoglycemia? When used alone or as add-on therapy with antihyperglycemic agents not associated with hypoglycemia, Sulisent showed a low incidence of hypoglycemia. Insulin and insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. When Sulisent was used as add-on therapy with insulin or an insulin secretagogue (e.g., sulfonylurea), the incidence of hypoglycemia was increased over that of placebo. Is there a significant increase in urine volume with Sulisent? In clinical studies, moderate increases (generally < ml) in daily urine volume were seen that attenuated over several days of dosing. What are the volume-depletion related Side Effects (S/Es)? In placebo-controlled clinical studies of Sulisent, increases in adverse reactions related to reduced intravascular volume (e.g. postural dizziness, orthostatic hypotension, or hypotension) were seen more commonly with the 300 mg dose and occurred most frequently in the first three months. Patients most susceptible to adverse reactions related to reduced intravascular volume include patients with moderate renal impairment, elderly patients, patients on loop diuretics and patients with low systolic blood pressure. The incidences of reduced intravascular volume-related adverse reactions were similar across Sulisent 100 mg, 300 mg and placebo groups (1.2%, 1.3% and 1.1%), respectively. The incidences of these adverse reactions with Sulisent in the two active-controlled studies were similar to comparators. Ref: Vaginal yeast infection fact sheet. Womenshealth.gov Web site. Accessed July 23, Canagliflozin Tablets 100 mg
8 Notes: Notes: Canagliflozin Tablets 100 mg
9
10
INVOKANA. canagliflozin hemihydrate NEW ZEALAND DATA SHEET
INVOKANA canagliflozin hemihydrate NEW ZEALAND DATA SHEET 1. PRODUCT NAME INVOKANA 100 mg film coated tablets INVOKANA 300 mg film coated tablets 2. QUALTITATIVE AND QUANTITATIVE COMPOSITION INVOKANA is
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Invokana 100 mg film-coated tablets Invokana 300 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Invokana
More informationINVOKANA PRODUCT INFORMATION
INVOKANA PRODUCT INFORMATION NAME OF THE MEDICINE Canagliflozin The chemical name is (1S) 1,5 anhydro 1 [3 [[5 (4 fluorophenyl) 2 thienyl]methyl] 4 methylphenyl] Dglucitol present in the tablets as the
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION Impairment in renal function: Monitor renal function during therapy. These highlights do not include all the information needed to use More frequent monitoring is
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationSummary of the risk management plan (RMP) for Vokanamet (canagliflozin / metformin)
EMA/137565/2014 Summary of the risk management plan (RMP) for Vokanamet (canagliflozin / metformin) This is a summary of the risk management plan (RMP) for Vokanamet, which details the measures to be taken
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationJARDIANCE PRODUCT MONOGRAPH. empagliflozin tablets. 10 mg and 25 mg. ATC Code: A10BK03 Sodium-glucose co-transporter 2 (SGLT2) inhibitors
PRODUCT MONOGRAPH Pr JARDIANCE empagliflozin tablets 10 mg and 25 mg ATC Code: A10BK03 Sodium-glucose co-transporter 2 (SGLT2) inhibitors Boehringer Ingelheim (Canada) Ltd 5180 South Service Rd Burlington,
More informationINVOKANA (canagliflozin) tablets, for oral use
(canagliflozin) tablets, for oral use Revised: 07/2017 076265-170714 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See
More informationBrand name: Steglatro. Generic name: Ertugliflozin (er too gli FLOE zin) Manufacturer: Merck
Brand name: Steglatro Generic name: Ertugliflozin (er too gli FLOE zin) Manufacturer: Merck Drug Class: Sodium-glucose co-transporter 2 (SGLT2) inhibitor Uses: Labeled: Indicated as adjunct to diet and
More informationPRODUCT MONOGRAPH INVOKANA. canagliflozin tablets. 100 mg and 300 mg as anhydrous canagliflozin
PRODUCT MONOGRAPH Pr canagliflozin tablets 100 mg and 300 mg as anhydrous canagliflozin ATC Code: A10BK02 Other blood glucose lowering drugs, excl. insulins Janssen Inc. 19 Green Belt Drive Toronto, Ontario
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION GLYXAMBI TM. empagliflozin and linagliptin tablets. 10 mg/5 mg and 25 mg/5 mg
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr GLYXAMBI TM empagliflozin and linagliptin tablets 10 mg/5 mg and 25 mg/5 mg ATC Code: A10BD19 Combinations of oral blood glucose lowering drugs
More informationINVOKAMET (canagliflozin and metformin hydrochloride) tablets for oral use
INVOKAMET (canagliflozin and metformin hydrochloride) tablets for oral use Revised: 08/2017 084131-171109 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed
More informationPRODUCT MONOGRAPH INVOKANA. canagliflozin tablets. 100 mg and 300 mg as anhydrous canagliflozin
PRODUCT MONOGRAPH Pr canagliflozin tablets 100 mg and 300 mg as anhydrous canagliflozin ATC Code: A10BK02 Other blood glucose lowering drugs, excl. insulins Janssen Inc. 19 Green Belt Drive Toronto, Ontario
More informationPRODUCT MONOGRAPH FORXIGA
PRODUCT MONOGRAPH dapagliflozin tablets (as dapagliflozin propanediol monohydrate) 5 mg and 10 mg ATC Code: A10BK01 Sodium-glucose co-transporter 2 (SGLT2) inhibitors AstraZeneca Canada Inc. 1004 Middlegate
More informationINVOKAMET XR (canagliflozin and metformin hydrochloride extended-release)
INVOKAMET XR (canagliflozin and metformin hydrochloride extended-release) tablets, for oral use Revised: 07/2017 076317-170714 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all
More informationSodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview
Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview Juan F. Mosley II, PharmD, CPh, AAHIVP; Lillian Smith, PharmD, CPh, MBA; Emily Everton,
More informationSTEGLATRO (ertugliflozin) tablets, for oral use Initial U.S. Approval: 2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STEGLATRO safely and effectively. See full prescribing information for STEGLATRO. STEGLATRO (ertugliflozin)
More informationThe Role of Renal Glucose Excretion in Adults with Type 2 Diabetes
You are cordially invited to attend the following promotional program: The Role of Renal Glucose Excretion in Adults with Type 2 Diabetes Program Information: 1126785 Thursday, March 13, 2014 at 6:30 PM
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationLabeled Uses: Indicated as a treatment of type 2 diabetes in adjunct with diet and exercise. Unlabeled Uses: No unlabeled uses have been indicated.
Brand Name: Steglatro Generic Name: ertugliflozin Manufacturer 1,5 : Merck Sharp & Dohme Corp. Drug Class 1,2,3,4,5 : Antidiabetic Agent, SGLT-2 inhibitor Uses 1,2,3,4,5 : Labeled Uses: Indicated as a
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationUS *Sections or subsections omitted from the full prescribing information are not listed.
US-15873 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (dapagliflozin) tablets, for
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationBrand Name: Farxiga. Generic Name: dapagliflozin. Manufacturer 1 : Bristol-Myers Squibb
Brand Name: Farxiga Generic Name: dapagliflozin Manufacturer 1 : Bristol-Myers Squibb Drug Class 1,3,4 : Antidiabetic, sodium-glucose cotransporter 2 (SGLT2) inhibitor Uses Labeled Uses 1,2,3,4,5 : Adjunct
More informationStudy Design: Prospective, Multicenter randomized, parallel-group, double blind, placebo controlled study.
Brand Name: Farxiga Generic Name: Dapagliflozin Manufacturer: Astra-Zenica Drug Class 1,2 : Antidiabetic agent, SGLT2 Inhibitor Uses: Labeled Uses 1,2,3,4 : Improving glycemic control in adults with type
More informationJARDIANCE (empagliflozin) tablets, for oral use Initial U.S. Approval: 2014
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (empagliflozin) tablets, for oral use
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationAUSTRALIAN PRODUCT INFORMATION - JARDIANCE empagliflozin film-coated tablets
AUSTRALIAN PRODUCT INFORMATION - JARDIANCE empagliflozin film-coated tablets 1 NAME OF THE MEDICINE empagliflozin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION JARDIANCE 10 mg film-coated tablets contains
More informationJARDIAMET. (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.
JARDIAMET (empagliflozin and metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg NAME OF THE MEDICINE JARDIAMET contains two oral antihyperglycaemic
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION INVOKAMET
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr INVOKAMET canagliflozin and metformin hydrochloride tablets (canagliflozin (as anhydrous canagliflozin) and metformin hydrochloride) 50 mg/500
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationIt is well understood that patients with type 2 diabetes (T2D) are
INFORMATION for the PHARMACIST This article was sponsored by Boehringer Ingelheim and Lilly. Addressing the Risk of Cardiovascular Mortality in Adult Patients with Type 2 Diabetes and Established Cardiovascular
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 7/2016
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GLYXAMBI safely and effectively. See full prescribing information for GLYXAMBI. GLYXAMBI (empagliflozin
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationSGLT-2 Inhibition in the Kidney: Changing Paradigms in the Treatment of Type 2 Diabetes Mellitus
A promotional supplement sponsored by: A supplement to www.pcmg-us.org INDUSTRY DIRECT SGLT-2 Inhibition in the Kidney: Changing Paradigms in the Treatment of Type 2 Diabetes Mellitus FACULTY Eden M. Miller,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationJARDIANCE TM PRODUCT MONOGRAPH. empagliflozin tablets. 10 mg and 25 mg. ATC Code: A10BX12 Other blood glucose lowering drugs, excl.
PRODUCT MONOGRAPH Pr TM empagliflozin tablets 10 mg and 25 mg ATC Code: A10BX12 Other blood glucose lowering drugs, excl. insulins Boehringer Ingelheim (Canada) Ltd 5180 South Service Rd Burlington, ON
More informationJARDIANCE. empagliflozin
JARDIANCE (empagliflozin) NAME OF THE MEDICINE Active Ingredient: Chemical name: empagliflozin (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3- yloxy]benzyl}phenyl)-d-glucitol Molecular formula:
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationCanagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin in combination therapy for treating type 2 Issued: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce
More informationAUSTRALIAN PRODUCT INFORMATION FORXIGA. (dapagliflozin propanediol monohydrate) Tablets
AUSTRALIAN PRODUCT INFORMATION FORXIGA (dapagliflozin propanediol monohydrate) Tablets 1 NAME OF THE MEDICINE The active ingredient in FORXIGA is dapagliflozin propanediol monohydrate. 2 QUALITATIVE AND
More informationSTEGLUJAN (ertugliflozin and sitagliptin) tablets, for oral use Initial U.S. Approval: 2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STEGLUJAN safely and effectively. See full prescribing information for STEGLUJAN. STEGLUJAN (ertugliflozin
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationSEGLUROMET (ertugliflozin and metformin hydrochloride) tablets, for oral use Initial U.S. Approval: 2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SEGLUROMET safely and effectively. See full prescribing information for SEGLUROMET. SEGLUROMET (ertugliflozin
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
US-16912 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use QTERN safely and effectively. See full prescribing information for QTERN. QTERN (dapagliflozin
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More information*Sections or subsections omitted from the full prescribing information are not listed.
US-13287 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XIGDUO XR safely and effectively. See full prescribing information for XIGDUO XR. XIGDUO
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Forxiga 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains dapagliflozin propanediol
More informationAUSTRALIAN PRODUCT INFORMATION GLYXAMBI empagliflozin and linagliptin filmcoated
AUSTRALIAN PRODUCT INFORMATION GLYXAMBI empagliflozin and linagliptin filmcoated tablets 1 NAME OF THE MEDICINE empagliflozin and linagliptin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION GLYXAMBI are film-coated
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationPeter Stein, MD Janssen Research and Development
New Agents and Technologies in the Pipeline for the Treatment of Patients with Diabetes Peter Stein, MD Janssen Research and Development Agents in Phase 3 Development for T2DM Long-acting GLP-1 analogues
More informationSafety, Tolerability, Pharmacokinetics,and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus Journal Club (May 2013) Sara Al-Sharhan, Pharm D intern-
More informationMetabolic acidosis, including diabetic ketoacidosis (1, 4, 5.1) History of serious hypersensitivity reaction to empagliflozin or metformin (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNJARDY XR safely and effectively. See full prescribing information for SYNJARDY XR. SYNJARDY XR
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Edistride 5 mg film-coated tablets Edistride 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Edistride
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationOral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus You should be offering psychosocial care to all patients with diabetes, says the ADA. Here are the specific recommendations. Summary Recommendation
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION SEGLUROMET
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION SEGLUROMET ertugliflozin and metformin hydrochloride tablets 2.5 mg/500 mg, 2.5 mg/1000 mg, 7.5 mg/500 mg, and 7.5 mg/1000 mg ertugliflozin /metformin
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION SYNJARDY TM. Empagliflozin and metformin hydrochloride tablets
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr SYNJARDY TM and metformin hydrochloride tablets 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, 12.5 mg/1000 mg Combinations
More informationPRODUCT MONOGRAPH. SANDOZ PIOGLITAZONE (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg Tablets. Anti-Diabetic Agent
PRODUCT MONOGRAPH Pr SANDOZ PIOGLITAZONE (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg Tablets Anti-Diabetic Agent Sandoz Canada Inc. 145 Jules-Léger Date of Revision: August 03, 2016 Boucherville,
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationMetformin Hydrochloride
Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin
More information7 DRUG INTERACTIONS 7.1 Drug Interactions with Empagliflozin 5.5 Acute Kidney Injury and Impairment in Renal Function
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GLYXAMBI safely and effectively. See full prescribing information for GLYXAMBI. GLYXAMBI (empagliflozin
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationPRODUCT MONOGRAPH. (pioglitazone hydrochloride) 15 mg, 30 mg and 45 mg Tablets. Manufacturer s Standard. Anti-Diabetic Agent
PRODUCT MONOGRAPH Pr MINT-PIOGLITAZONE (pioglitazone hydrochloride) 15 mg, 30 mg and 45 mg Tablets Manufacturer s Standard Anti-Diabetic Agent Mint Pharmaceuticals Inc. Date of Revision: 1093 Meyerside
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationDiabetes is a chronic disease associated with a variety
n REPORTS n Attainment of Diabetes-Related Quality Measures With Canagliflozin Versus Sitagliptin Robert A. Bailey, MD; C. V. Damaraju, PhD; Silas C. Martin, MS; Gary E. Meininger, MD; Marcia F. T. Rupnow,
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationDiabetes and the Elderly: Medication Considerations When Determining Benefits and Risks
Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Gretchen M. Ray, PharmD, PhC, BCACP, CDE Associate Professor UNM College of Pharmacy September 7 th, 2018 DISCLOSURES
More informationCost Effectiveness of canagliflozin (Invokana )
Cost Effectiveness of canagliflozin (Invokana ) for adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on therapy with other anti-hyperglycaemic agents including insulin,
More informationInnovative, Unusual Therapies for DM-2: Insulin U-500, Bromocriptine, Colesevelam, and SGLT2 inhibitors. April 3 rd, 2014
Innovative, Unusual Therapies for DM-2: Insulin U-500, Bromocriptine, Colesevelam, and SGLT2 inhibitors April 3 rd, 2014 KM Pantalone Associate Staff Endocrinology Speaker Bureau: Disclosures Bristol-Myers
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationHistory of serious hypersensitivity reaction to empagliflozin, metformin or any of the excipients in SYNJARDY (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNJARDY safely and effectively. See full prescribing information for SYNJARDY. SYNJARDY (empagliflozin
More informationTechnology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288
Dapagliflozin in combination therapy for treating type 2 diabetes Technology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288 NICE 2018. All rights reserved. Subject to Notice of rights
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationProduct Monograph. Published by
Product Monograph Published by INDICATION AND LIMITATIONS OF USE tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Komboglyze 2.5 mg/850 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg of saxagliptin
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More information